Organovo Holdings, Inc. (ONVO)
NASDAQ: ONVO · Real-Time Price · USD
0.461
-0.001 (-0.22%)
At close: Oct 22, 2024, 4:00 PM
0.469
+0.008 (1.78%)
Pre-market: Oct 23, 2024, 6:45 AM EDT
Organovo Holdings Revenue
Organovo Holdings had revenue of $39.00K in the quarter ending June 30, 2024, a decrease of -48.00%. This brings the company's revenue in the last twelve months to $73.00K, down -83.60% year-over-year. In the fiscal year ending March 31, 2024, Organovo Holdings had annual revenue of $109.00K, down -70.54%.
Revenue (ttm)
$73.00K
Revenue Growth
-83.60%
P/S Ratio
67.14
Revenue / Employee
$3,650
Employees
20
Market Cap
7.08M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionONVO News
- 3 months ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
- 3 months ago - Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis - GlobeNewsWire
- 5 months ago - Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease - GlobeNewsWire
- 5 months ago - Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) - GlobeNewsWire
- 5 months ago - Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering - GlobeNewsWire
- 6 months ago - Organovo's fatty liver disease drug meets main goal in mid-stage study - Reuters
- 6 months ago - Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo - GlobeNewsWire
- 9 months ago - Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress - GlobeNewsWire